Despite pertinent pandemic pressures and tough comps (due to panic buying), Sanofi reported decent growth in Q1 21 – driven by robust growth in the Dupixent and vaccine business. Moreover, profitability improved further due to the cost initiatives measures in place. While pandemic-induced uncertainties are here to stay, the group should find support from new launches and label and geographic expansion of key drugs. Additionally, success in the COVID-19 vaccine development space could prove anoth ....
